Strategic Partnerships Beacon Biosignals has established strategic partnerships with notable companies like Longboard Pharmaceuticals, Takeda, and Gate Neuro, showcasing potential collaboration opportunities for mutual benefit and revenue growth.
Key Personnel Addition The hiring of David Matthews, PhD, as the Chief Business Officer at Beacon Biosignals brings valuable expertise and leadership, indicating a potential focus on expanding business opportunities and driving sales growth under new leadership.
Acquisitions and Integrations Beacon Biosignals' acquisitions of assets from Dreem and integration of Dreem 2's hardware into their platform present an opportunity for leveraging new technologies, expanding product offerings, and potentially tapping into Dreem's customer base for increased sales.
Awards and Recognition Recognition in pitch competitions like MassMEDIC IGNITE and Harvard i-Lab President's Innovation Challenge enhances Beacon Biosignals' credibility and visibility, potentially attracting more investors, partners, and customers, leading to increased sales opportunities.
Focus on Precision Medicine Beacon Biosignals' focus on precision EEG biomarkers, as evidenced by collaborations in Major Depressive Disorder and sleep disorders, positions the company as a leader in personalized medicine solutions, offering potential opportunities for specialized healthcare partnerships and increased sales in the healthcare sector.
134
$10M
37$10M
51$10M$50M
93K$1B
135$10M$50M
203$10M$50M
487$50M$100MBeacon Biosignals uses 8 technology products and services including Google Analytics, Databricks, HubSpot, and more. Explore Beacon Biosignals's tech stack below.
| Beacon Biosignals Email Formats | Percentage |
| First.Last@beacon.bio | 81% |
| First@beacon.bio | 15% |
| Last@beacon.bio | 2% |
| First.L@beacon.bio | 2% |
Software DevelopmentMassachusetts, United States51-200 Employees
Beacon's AI platform for brain data enables and accelerates new treatments that transform the lives of patients with neurological and psychiatric disease. Through FDA-cleared EEG wearables, novel machine learning algorithms, enormous datasets, and advances in software engineering, we are changing the way patients are treated for disorders of the brain.
Company Overview
Media & News
Funding & FinancialsBeacon Biosignals's revenue is in the range of $10M
Funding & FinancialsBeacon Biosignals's revenue is in the range of $10M
1-888-653-2347 
support@leadiq.com